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SUMMARY
Background
Intestinal metaplasia (Barrett’s oesophagus), but not cardiac-type mucosa
in columnar-lined oesophagus, is regarded as premalignant. As intestinal
metaplasia and cardiac-type mucosa are endoscopically indiscernible, it
is difficult to take targeted samples from columnar-lined oesophagus
with consequently a risk of having undetected intestinal metaplasia.
Aim
To investigate whether the intestinal markers CDX2, MUC2 and villin
can predict the presence of undetected intestinal metaplasia in colum-
nar-lined oesophagus.
Methods
Presence of intestinal metaplasia or cardiac-type mucosa was identified
in 122 biopsy sets of columnar-lined oesophagus from 61 patients, col-
lected at two subsequent follow-up upper endoscopies. CDX2, MUC2
and villin expression were determined by immunohistochemistry.
Results
All intestinal metaplasia samples (55) were positive for CDX2 and
MUC2 and 32 of 55 for villin. CDX2 expression was detected in 23 of
67 (34%) samples with only cardiac-type mucosa. Detection of CDX2 in
cardiac-type mucosa increased the likelihood of finding intestinal
metaplasia in another biopsy set of columnar-lined oesophagus (odds
ratio 3.5, 95% CI ¼ 1.2–10, P ¼ 0.02). MUC2 was positive in 13 of 23
(57%) of CDX2-positive cardiac-type mucosa samples, whereas villin
was detected in seven of 23 (30%).
Conclusions
CDX2 expression in cardiac-type mucosa might be able to predict the
presence of undetected intestinal metaplasia in columnar-lined oesopha-
gus, and thus may be a putative marker for the presence of intestinal
metaplasia in the absence of goblet cells.
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INTRODUCTION
Barrett’s oesophagus (BO) is a premalignant condition
caused by chronic gastro-oesophageal reflux,1 which
can progress from low-grade dysplasia to high-grade
dysplasia, and subsequently to oesophageal adenocar-
cinoma.2–5
Barrett’s oesophagus is characterized by the replace-
ment of the squamous epithelium of the oesophagus
by columnar epithelium with goblet cells [specialized
intestinal metaplasia (IM)].6 IM is associated with the
expression of intestinal markers such as MUC2,7 and
villin.8 Cardiac-type mucosa (CM) is also frequently
observed in the columnar-lined oesophagus (CLO),9
with the absence of goblet cells as the only histologi-
cal difference compared with IM.10 CM, in contrast to
IM, is not regarded as a premalignant condition.5, 11
Therefore, only patients with IM are currently advised
to undergo periodic endoscopic surveillance to detect
progression to dysplasia in an early, potentially cur-
able stage.12 Others have reported that patients with
biopsies from CLO without IM were at an increased
risk of having undetected IM. This was explained by
either sampling error or developing IM over time.
According to current guidelines, these patients would
have been falsely excluded from a surveillance
programme.13
The homeobox protein CDX2 is a transcription fac-
tor involved in the early intestinal differentiation of
the epithelium of the intestines,14–16 and its expression
is also linked with BO,17–19 suggesting that CDX2 is
an early marker for the development of IM in the
oesophagus as well. CDX2 regulates transcription of
several intestinal genes, encoding proteins such as
MUC2, alkaline phosphatase and sucrase-isomal-
tase.20, 21 It has been reported that intestinal pheno-
typic modifications may also be detected in the
absence of goblet cells by CDX2 expression in
CLO.22, 23 This epithelium has been regarded as being
early-stage BO, but these studies were cross-sectional
and therefore provided not enough evidence for this
hypothesis.
The aim of this longitudinal study was to investigate
whether intestinal markers for IM, i.e. CDX2 (early
intestinal marker), MUC2 (goblet cell marker) and vil-
lin (late intestinal marker), were present in the colum-
nar-lined segment of the oesophagus in the absence of
a histological diagnosis of IM (defined by the presence
of goblet cells). Furthermore, we investigated whether
these markers were predictive for the presence of IM




In this multicentre study, 108 patients were evaluated
for this retrospective study for the presence of an
endoscopic CLO of at least 2 cm, and at least two fol-
low-up endoscopies with biopsies being performed.
Based on these inclusion criteria, 47 patients were
excluded, and consequently 61 patients could be
included in this study. Biopsies were taken at different
levels from the CLO and embedded together in one
paraffin block. In this study, sections of these paraffin-
embedded biopsy sets were used for evaluation. These
slides were reviewed for the presence of IM by an
expert gastrointestinal pathologist (HvD). Based on
the presence of IM, patients were divided into three
groups (Table 1): patients with IM in both biopsy sets
(IM-group), patients with IM in one biopsy set and
with only CM in the other biopsy set (discordant-
group), and patients with only CM in both biopsy sets
(CM-group). Patients with CM in the first endoscopy
and IM in the second endoscopy, and visa versa, were
taken together as the discordant-group.
Histology and immunohistochemistry
Six consecutive sections of 4 lm each from every
biopsy set were mounted on adhesive slides, dried
overnight at 37 C, and deparaffinized with xylene.
The first of these serially sectioned slides was stained
with haematoxylin and eosin (H&E) to determine the
type of columnar epithelium (CM or IM). Alcian Blue
and periodic acid-Schiff (PAS) stainings in consecutive
Table 1. Classification of patients in groups, based on




First endoscopy IM IM CM CM
Second
endoscopy
IM CM IM CM
No. of patients 15 16 9 21
IM, intestinal metaplasia; CM, cardiac-type mucosa.
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slides were performed to facilitate the detection of
mucin producing goblet cells. The next three slides
were used for immunohistochemistry.
For immunohistochemistry, antigen retrieval was
performed by boiling the deparaffinized samples in
10 mM monocitric acid buffer (pH 6.0) for 15 min, and
slowly cooling down to room temperature (RT). Prior
to immune staining, endogenous peroxidase activity
was blocked by incubating the slides in a 0.5% solu-
tion of H2O2 in phosphate-buffered citric acid for
15 min at RT. Samples were washed for 5 min with
TRIS-buffered saline (TBS) (pH 7.4). This was repeated
two times. The samples were incubated in TBS buffer
containing 10% rabbit non-immune serum (Dako,
Glostrup, Denmark) and 10% normal human plasma
(Dako) for 20 min. Sections were incubated for 16 h at
4 C with respectively primary antibody anti-CDX2
(clone 392M; Biogenex, San Ramon CA, USA) in a
1:100 dilution, anti-MUC2 (clone Ccp58; Novocastra,
Newcastle upon Tyne, UK) in a 1:100 dilution or anti-
villin (clone CWWB1; Lab Vision, Fremont CA, USA)
in a 1:2000 dilution. Samples were again washed three
times for 5 min with TBS (pH 7.4). Subsequently, bio-
tin-labelled rabbit-anti-mouse antibody (Dako) was
used as second antibody, followed by the addition of a
streptavidin–horseradish peroxidase complex (Dako)
using 3-amino-9-ethylcarbazole as substrate. Slides
were analysed for nuclear CDX2 staining, cytoplasmic
MUC2 staining and brush border villin staining by two
independent investigators (MK, DAB) who were
blinded for the presence or absence of IM. CDX2
expression was considered positive if a clear red stain-
ing of at least five adjacent nuclei in the same gland
was seen, to exclude incidental false positive nuclei.
MUC2 expression was present if a red staining in the
cytoplasm of (goblet) cells was observed. Villin expres-
sion was visualized as a red staining near the apical
border of cells.
Statistical analysis
The chi-squared test, Mann–Whitney test and Kruskal–
Wallis test were used to compare the patient character-
istics and the immunohistochemical stainings between
the three patient groups. A P-value <0.05 was consid-
ered significant. Odds ratios (ORs) with a 95% confi-
dence interval were used as an estimate of the relative
risk for the presence of IM. Calculations were initially
done with upper endoscopies as the unit of analysis,
ignoring the statistical dependency of endoscopies
within the same patients. Subsequently, analyses were
repeated with the consideration of only one endoscopy
per patient. Statistic analyses were conducted using
SPSS software (SPSS version 11.0; SPSS, Chicago, IL,
USA).
RESULTS
The presence of IM
Intestinal metaplasia was defined as the presence of
goblet cell containing glands. In addition to goblet
cells, non-goblet cells can also stain positive with
alcian blue. Therefore, the presence of IM was evalu-
ated by light-microscopic examination of H&E stained
slides. Consecutive alcian blue and PAS stained slides
were only used to confirm a diagnosis of IM.
Intestinal metaplasia was observed in 55 of 122
(45%) biopsy sets. In 67 of 122 (55%) biopsy sets, only
CM was present. The mean number of biopsies taken
was five in the IM-group and four in the discordant-
and CM-group (similar at the two endoscopies in each
group), which was not significantly different (Table 2).
When correcting for the length of the columnar seg-
ment, the mean number of biopsies taken per centi-
metre was not different in IM and CM biopsy sets
(respectively 1.5/cm (range 0.1–4.3) and 1.5/cm (range
0.3–4.0), P ¼ 0.68). Based on the presence of IM, the
IM-group consisted of 15 patients, the discordant-
group of 25 patients, and the CM-group of 21 patients.
Of all patient characteristics, only the length of the CLO
differed significantly between the three groups (P ¼
0.016), with CLO being longer in the IM-group, com-
pared with the discordant- and the CM-group (Table 2).
CDX2 expression
To investigate the expression of CDX2 protein in IM
and CM, CDX2 staining was evaluated. CDX2 expres-
sion was observed in all IM-positive biopsy sets
(Table 3; Figure 1a,b), i.e. in 30 of the IM-group and in
25 of the discordant-group. In addition, CDX2 expres-
sion was also observed in 23 of 67 (34%, 95% CI: 23–
47) biopsy sets without IM (Table 3; Figure 1c,d).
CDX2 was more frequently observed in IM-negative
biopsy sets of patients of the discordant-group, in
which the other biopsy set was positive for IM (13/25;
52%), than in patients of the CM-group, in which IM
was absent in both biopsy sets (10/42; 24%) (P ¼
0.019). The presence of CDX2 in CM therefore
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significantly increased the likelihood of observing IM
in another biopsy set of the CLO (OR 3.5, 95% CI: 1.2–
10, P ¼ 0.021), regardless if CM in the discordant-group
was present in biopsies from the first or second upper
endoscopy. When we calculated the predictive value of
CDX2 expression in biopsies with CM taken during the
first endoscopy, for the presence of IM in biopsies of the
next endoscopy, and visa versa, the ORs were similar
(respectively 4.0, 95% CI: 0.8–21, P ¼ 0.10 and 3.2,
95% CI: 0.8–13, P ¼ 0.10). In one patient of group 3,
both IM-negative biopsies were positive for CDX2.
A longer segment of CLO was not associated with a
higher change of CDX2 being present in CM (P ¼
0.135). There was no correlation between the use of
proton-pump inhibitors and the presence of CDX2 in
CM (P ¼ 0.42).
MUC2 expression
Mucins are large glycoproteins forming the main
components of the gel-like mucous layer on the sur-
face of the intestine, protecting the mucosa against
damaging luminal contents, such the gastro-oeso-
phageal refluxate.24 MUC2 is a mucin specific for
IM.25–27 As CDX2 regulates the transcription of
MUC2,21 we evaluated the expression of MUC2 in IM
and CM. MUC2 staining in goblet cells was found in
all biopsy sets with IM (Table 3, Figure 2a), and was
mainly localized in the cytoplasm alongside the
membrane. Moreover, MUC2 was also expressed in
CM in 16 of 67 (24%) samples without IM. In CM,
MUC2 was expressed in the entire cytoplasm of non-
goblet columnar cells that did not stain positive with
alcian blue (Figure 2b). Thirteen of 16 (81%) MUC2-
positive CM samples were also positive for CDX2 in
the same region.
Villin expression
Villin is an actin-binding cytoskeletal protein essen-
tial for brush border formation (microvilli) in normal
end-differentiated epithelial cells of the intestine.28
Table 2. Patients characteristics
IM-group Discordant-group CM-group P-value
No. of patients 15 25 21
Mean age at first endoscopy in years (range) 59 (28–82) 58 (39–78) 52 (27–74) 0.30
Mean length of the CLO in cm (range) 4 (2–8)* 3 (2–7) 3 (2–5) 0.016
Mean number of biopsies (range) 5 (1–17) 4 (1–7) 4 (1–8) 0.27
Interval between subsequent endoscopies in months (range) 42 (12–158) 31 (4–112) 30 (4–117) 0.54
Proton-pump inhibitor use (%) 11/13 (85%) 20/22 (91%) 12/19 (63%) 0.18
IM, intestinal metaplasia; CM, cardiac-type mucosa; CLO, columnar-lined oesophagus.
* Significantly different.
Table 3. Results of immunohistochemical stainings of all biopsy sets
Group (no. pts)
IM CM
IM (30) Discordant (25) Total (55) Discordant (25) CM (42) Total (67)
CDX2-positive 30 (100%) 25 (100%) 55 (100%) 13 (52%)** 10 (24%) 23 (34%)
MUC2-positive 30 (100%) 25 (100%) 55 (100%) 11 (44%) 5 (12%) 16 (24%)
Villin-positive 22 (73%) 10 (40%) 32 (58%) 4 (17%)* 3 (7%) 7 (10%)
IM, intestinal metaplasia; CM, cardiac-type mucosa.
* One sample could not be evaluated as no enough tissue was available.
** P ¼ 0.019 (compared with CDX2 expression in biopsy sets with CM of the CM-group).
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Therefore, the presence of a brush border of the
oesophageal columnar epithelium can be demonstra-
ted by villin expression. We investigated whether vil-
lin protein was also expressed in CM in addition to
the intestinal markers CDX2 and MUC2. One CM
sample could not be evaluated, as there was not
enough tissue available for staining. Villin expression
was observed in 32 of 55 (58%) of IM-positive biopsy
sets (Figure 3a). In seven of 66 (11%) CM samples,
villin expression was found (Figure 3b), of which
five were also CDX2 positive. Four CM samples (6%)
were positive for CDX2 and MUC2, as well as for
villin.
DISCUSSION
Patients with CM in CLO are currently excluded from
surveillance endoscopy, as they are regarded as IM
negative and thus as not having a premalignant condi-
tion.13 This study shows a significant relationship
between the intestinal marker CDX2 in CM and the
presence of IM in biopsies taken at another time point,
as CDX2 stained positive in 52% of CM biopsy sets of
the discordant-group (with an OR of 3.5), in which the
biopsy set of the other endoscopy was positive for IM
(Table 2). In our opinion it is unlikely that, despite the
two-dimensional analysis of the biopsies, goblet cells
Figure 1. CDX2 expression in columnar epithelium of the oesophagus. (a) Intestinal-type columnar epithelium with goblet
cells (haematoxylin-eosin). (b) Nuclear staining (red) for CDX2 in intestinal-type columnar epithelium in a serial section of
the same patient as in (a). (c) Cardiac-type columnar epithelium without goblet cells (haematoxylin-eosin). (d) CDX2
expression in cardiac-type columnar epithelium in a serial section of the same patient as in (c). Original magnifications
·100.
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have been missed in these CM biopsy sets, as the
CDX2 expression was often observed in large areas
without goblet cells (Figure 1c,d), and, in addition, in
the six consecutive slides also no goblet cells were
observed. Therefore, CDX2 staining may represent a
useful histological marker for the presence of IM in
CLO despite the absence of goblet cells suggestive for
IM.
CDX2 expression in CM as an indicator for the pres-
ence of IM has been reported in previous studies.19, 22
These studies were however cross-sectional, which
means that biopsies were only evaluated at one time-
point. In contrast, this study was a longitudinal study,
in which biopsy sets of two subsequent endoscopies
were compared.
Previously, it has been suggested that there are two
possible reasons for not detecting IM.13 First, several
authors have proposed that IM may develop over time
in a two-step process. It has been suggested that
multilayered epithelium, with morphological and
immunohistochemical characteristics of both squa-
mous and columnar epithelium, may represent a trans-
itional stage in the development of BO.29 Others have
suggested that IM develops from previously induced
CM in the oesophagus under influence of chronic
inflammation.13, 30–32 According to this theory, the
finding of CDX2 expression in CM, and in a subset
also expression of MUC2 and villin, could indicate
early intestinal differentiation prior to morphologic
changes such as goblet cells,19, 33 and in this way
being an intermediate stage in the differential shift of
CM towards IM.28, 30
The second possibility for not detecting IM is samp-
ling error. Although IM is predominantly present in
the proximal end of the CLO,34 IM and CM may have
a patchy distribution. As IM and CM are endoscopically
indiscernible from each other, and the presence of IM
can be very focal,35 sampling error for the detection
(b)(a)
Figure 2. MUC2 expression in columnar epithelium of the oesophagus. (a) MUC2 staining in goblet cells (red) in intestinal-
type columnar epithelium. (b) MUC2 expression in cardiac-type columnar epithelium without goblet cells in a serial section
of the same patient as in Figure 1c. Note that the MUC2 expression is not associated with goblet cells. Original magnifica-
tions ·100.
(b)(a)
Figure 3. Villin expression in columnar epithelium of the oesophagus. (a) Villin staining of the brush border (red) in intes-
tinal-type columnar epithelium. (b) Villin expression in cardiac-type columnar epithelium without goblet cells. Note that
the villin expression is not associated with goblet cells. Original magnifications ·200.
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of IM may occur.13 Sixteen of the 25 patients of the
discordant-group had IM in their first, and CM in their
second biopsy set (Table 1). It seems likely that in these
cases the finding of no IM can be contributed to samp-
ling error. The likelihood of detecting IM increased
with the number of biopsies taken, and therefore taking
not enough biopsies could be a reasonable explanation
for missing IM in this group. As in this study the mean
number of biopsies taken per cm was similar in the IM
samples and the CM samples, the possibility of samp-
ling error seems to be ruled out. However, as IM has a
patchy appearance in the CLO but is predominantly
located at the proximal end of the CLO,12, 34 it is poss-
ible that despite taking the same numbers of biopsies,
IM could be missed due to taking proportionally less
biopsies of the proximal part of the CLO. A similar
explanation can be given for the other nine patients of
the discordant-group who had CM detected at their
first endoscopy, whereas IM was found in biopsies from
the second endoscopy. As the mean interval between
two subsequent endoscopies in the discordant-group
was with 30 months relatively long, and the develop-
ment of IM is thought to be a slow process, it is also
possible that IM in this subgroup has developed over
time.
Although a final conclusion on the cause of not
detecting IM in one set of biopsies cannot be given,
the ORs for the predicting value of CDX2 in CM in the
different subgroups were similar, and thus it is reason-
able to assume that CDX2 expression in CM represents
a reliable marker for the detection of the premalignant
IM in CLO at another time point. In line with this
assumption, it is likely that the 24% with CDX2
expression in CM biopsy sets in whom IM was not
detected in both biopsy sets taken at different time
points, will show IM in biopsies taken at a next endo-
scopy. Unfortunately, because of exclusion from the
surveillance programme, these patients have currently
not undergone another follow-up upper endoscopy to
evaluate this.
CDX2 is a transcription factor for MUC2, which is a
mucin specific for IM.25–27 In our study, as expected,
all IM biopsies stained positive for MUC2. In 13 of 23
(57%) of the CDX2-positive CM biopsies, MUC2 stain-
ing was also positive. Villin expression was observed
in 58% of the IM-positive samples. This lower result of
villin expression in IM compared with CDX2 expres-
sion and MUC2 expression has been suggested to be
caused by the fact that the quantity of villin protein
needs to have a sufficient level to result in a mature
brush border.36, 37 In addition to villin expression in
IM, five of 23 (22%) of the CDX2-positive CM samples
also showed villin expression, suggesting the presence
of end-differentiated intestinal characteristics in CM.
Although less frequent, the presences of MUC2 and
villin expression in CM are supportive for the value of
CDX2 as indicator of IM in CLO.
A possible limitation of this study is the use of one
single technique to detect CDX2 in the biopsies. The
major reason that we only used immunohistochemistry
was that additional techniques such RT-PCR,18 could
not be performed on our paraffin-embedded tissue, but
only on fresh snap frozen biopsies, which were not
available in this retrospective study. However, as we
performed the CDX2 immunohistochemical stainings
with a commonly used dilution,17, 18 which showed
only very specific nuclear staining without back-
ground staining in the cytoplasm of cells, it is unlikely
that the immunohistochemistry may have resulted in
false positive results.
In conclusion, this study shows that the presence of
CDX2 in CM might be able to predict the presence of
IM in CLO, which was otherwise not detected because
of sampling error or developing of IM over time. This
suggests that CDX2 staining could be used as an addi-
tional marker for the presence of IM in CLO in the
absence of goblet cells. A prospective follow-up study
on patients with CM in their biopsies should be per-
formed to confirm the predictive value of CDX2.
Nonetheless, as the presence of IM is still the gold
standard for the presence of premalignant BO, we sug-
gest an additional endoscopy in patients in whom
CDX2 expression in CM is demonstrated. This should
include the taking of extensive biopsies for the detec-
tion of IM (especially near the squamo–columnar junc-
tion) to evaluate if endoscopic surveillance is indeed
indicated in these patients.
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